Yuvaraj Mahendran1,2, Anna Jonsson1, Christian T Have1, Kristine H Allin1, Daniel R Witte2,3, Marit E Jørgensen4, Niels Grarup1, Oluf Pedersen1, Tuomas O Kilpeläinen1, Torben Hansen5. 1. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, 2100, Copenhagen, Denmark. 2. The Danish Diabetes Academy, Odense, Denmark. 3. Institute of Public Health, University of Aarhus, Aarhus, Denmark. 4. Steno Diabetes Center, Gentofte, Denmark. 5. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, 2100, Copenhagen, Denmark. torben.hansen@sund.ku.dk.
Abstract
AIMS/HYPOTHESIS: Fasting plasma levels of branched-chain amino acids (BCAAs) are associated with insulin resistance, but it remains unclear whether there is a causal relation between the two. We aimed to disentangle the causal relations by performing a Mendelian randomisation study using genetic variants associated with circulating BCAA levels and insulin resistance as instrumental variables. METHODS: We measured circulating BCAA levels in blood plasma by NMR spectroscopy in 1,321 individuals from the ADDITION-PRO cohort. We complemented our analyses by using previously published genome-wide association study (GWAS) results from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) (n = 46,186) and from a GWAS of serum BCAA levels (n = 24,925). We used a genetic risk score (GRS), calculated using ten established fasting serum insulin associated variants, as an instrumental variable for insulin resistance. A GRS of three variants increasing circulating BCAA levels was used as an instrumental variable for circulating BCAA levels. RESULTS: Fasting plasma BCAA levels were associated with higher HOMA-IR in ADDITION-PRO (β 0.137 [95% CI 0.08, 0.19] p = 6 × 10-7). However, the GRS for circulating BCAA levels was not associated with fasting insulin levels or HOMA-IR in ADDITION-PRO (β -0.011 [95% CI -0.053, 0.032] p = 0.6 and β -0.011 [95% CI -0.054, 0.031] p = 0.6, respectively) or in GWAS results for HOMA-IR from MAGIC (β for valine-increasing GRS -0.012 [95% CI -0.069, 0.045] p = 0.7). By contrast, the insulin-resistance-increasing GRS was significantly associated with increased BCAA levels in ADDITION-PRO (β 0.027 [95% CI 0.005, 0.048] p = 0.01) and in GWAS results for serum BCAA levels (β 1.22 [95% CI 0.71, 1.73] p = 4 × 10-6, β 0.96 [95% CI 0.45, 1.47] p = 3 × 10-4, and β 0.67 [95% CI 0.16, 1.18] p = 0.01 for isoleucine, leucine and valine levels, respectively) and instrumental variable analyses in ADDITION-PRO indicated that HOMA-IR is causally related to higher circulating fasting BCAA levels (β 0.73 [95% CI 0.26, 1.19] p = 0.002). CONCLUSIONS/ INTERPRETATION: Our results suggest that higher BCAA levels do not have a causal effect on insulin resistance while increased insulin resistance drives higher circulating fasting BCAA levels.
AIMS/HYPOTHESIS: Fasting plasma levels of branched-chain amino acids (BCAAs) are associated with insulin resistance, but it remains unclear whether there is a causal relation between the two. We aimed to disentangle the causal relations by performing a Mendelian randomisation study using genetic variants associated with circulating BCAA levels and insulin resistance as instrumental variables. METHODS: We measured circulating BCAA levels in blood plasma by NMR spectroscopy in 1,321 individuals from the ADDITION-PRO cohort. We complemented our analyses by using previously published genome-wide association study (GWAS) results from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) (n = 46,186) and from a GWAS of serum BCAA levels (n = 24,925). We used a genetic risk score (GRS), calculated using ten established fasting serum insulin associated variants, as an instrumental variable for insulin resistance. A GRS of three variants increasing circulating BCAA levels was used as an instrumental variable for circulating BCAA levels. RESULTS: Fasting plasma BCAA levels were associated with higher HOMA-IR in ADDITION-PRO (β 0.137 [95% CI 0.08, 0.19] p = 6 × 10-7). However, the GRS for circulating BCAA levels was not associated with fasting insulin levels or HOMA-IR in ADDITION-PRO (β -0.011 [95% CI -0.053, 0.032] p = 0.6 and β -0.011 [95% CI -0.054, 0.031] p = 0.6, respectively) or in GWAS results for HOMA-IR from MAGIC (β for valine-increasing GRS -0.012 [95% CI -0.069, 0.045] p = 0.7). By contrast, the insulin-resistance-increasing GRS was significantly associated with increased BCAA levels in ADDITION-PRO (β 0.027 [95% CI 0.005, 0.048] p = 0.01) and in GWAS results for serum BCAA levels (β 1.22 [95% CI 0.71, 1.73] p = 4 × 10-6, β 0.96 [95% CI 0.45, 1.47] p = 3 × 10-4, and β 0.67 [95% CI 0.16, 1.18] p = 0.01 for isoleucine, leucine and valine levels, respectively) and instrumental variable analyses in ADDITION-PRO indicated that HOMA-IR is causally related to higher circulating fasting BCAA levels (β 0.73 [95% CI 0.26, 1.19] p = 0.002). CONCLUSIONS/ INTERPRETATION: Our results suggest that higher BCAA levels do not have a causal effect on insulin resistance while increased insulin resistance drives higher circulating fasting BCAA levels.
Authors: Helle Krogh Pedersen; Valborg Gudmundsdottir; Henrik Bjørn Nielsen; Tuulia Hyotylainen; Trine Nielsen; Benjamin A H Jensen; Kristoffer Forslund; Falk Hildebrand; Edi Prifti; Gwen Falony; Emmanuelle Le Chatelier; Florence Levenez; Joel Doré; Ismo Mattila; Damian R Plichta; Päivi Pöhö; Lars I Hellgren; Manimozhiyan Arumugam; Shinichi Sunagawa; Sara Vieira-Silva; Torben Jørgensen; Jacob Bak Holm; Kajetan Trošt; Karsten Kristiansen; Susanne Brix; Jeroen Raes; Jun Wang; Torben Hansen; Peer Bork; Søren Brunak; Matej Oresic; S Dusko Ehrlich; Oluf Pedersen Journal: Nature Date: 2016-07-13 Impact factor: 49.962
Authors: Stephen Turner; Loren L Armstrong; Yuki Bradford; Christopher S Carlson; Dana C Crawford; Andrew T Crenshaw; Mariza de Andrade; Kimberly F Doheny; Jonathan L Haines; Geoffrey Hayes; Gail Jarvik; Lan Jiang; Iftikhar J Kullo; Rongling Li; Hua Ling; Teri A Manolio; Martha Matsumoto; Catherine A McCarty; Andrew N McDavid; Daniel B Mirel; Justin E Paschall; Elizabeth W Pugh; Luke V Rasmussen; Russell A Wilke; Rebecca L Zuvich; Marylyn D Ritchie Journal: Curr Protoc Hum Genet Date: 2011-01
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: Pengxiang She; Cynthia Van Horn; Tanya Reid; Susan M Hutson; Robert N Cooney; Christopher J Lynch Journal: Am J Physiol Endocrinol Metab Date: 2007-10-09 Impact factor: 4.310
Authors: Denise E Lackey; Christopher J Lynch; Kristine C Olson; Rouzbeh Mostaedi; Mohamed Ali; William H Smith; Fredrik Karpe; Sandy Humphreys; Daniel H Bedinger; Tamara N Dunn; Anthony P Thomas; Pieter J Oort; Dorothy A Kieffer; Rajesh Amin; Ahmed Bettaieb; Fawaz G Haj; Paska Permana; Tracy G Anthony; Sean H Adams Journal: Am J Physiol Endocrinol Metab Date: 2013-03-19 Impact factor: 4.310
Authors: Pengxiang She; Kristine C Olson; Yoshihiro Kadota; Ayami Inukai; Yoshiharu Shimomura; Charles L Hoppel; Sean H Adams; Yasuko Kawamata; Hideki Matsumoto; Ryosei Sakai; Charles H Lang; Christopher J Lynch Journal: PLoS One Date: 2013-03-20 Impact factor: 3.240
Authors: Anne-Louise S Hansen; Bendix Carstensen; Jørn W Helge; Nanna B Johansen; Bibi Gram; Jens S Christiansen; Søren Brage; Torsten Lauritzen; Marit E Jørgensen; Mette Aadahl; Daniel R Witte Journal: Diabetes Care Date: 2013-06-11 Impact factor: 19.112
Authors: Johannes Kettunen; Ayşe Demirkan; Peter Würtz; Harmen H M Draisma; Toomas Haller; Rajesh Rawal; Anika Vaarhorst; Antti J Kangas; Leo-Pekka Lyytikäinen; Matti Pirinen; René Pool; Antti-Pekka Sarin; Pasi Soininen; Taru Tukiainen; Qin Wang; Mika Tiainen; Tuulia Tynkkynen; Najaf Amin; Tanja Zeller; Marian Beekman; Joris Deelen; Ko Willems van Dijk; Tõnu Esko; Jouke-Jan Hottenga; Elisabeth M van Leeuwen; Terho Lehtimäki; Evelin Mihailov; Richard J Rose; Anton J M de Craen; Christian Gieger; Mika Kähönen; Markus Perola; Stefan Blankenberg; Markku J Savolainen; Aswin Verhoeven; Jorma Viikari; Gonneke Willemsen; Dorret I Boomsma; Cornelia M van Duijn; Johan Eriksson; Antti Jula; Marjo-Riitta Järvelin; Jaakko Kaprio; Andres Metspalu; Olli Raitakari; Veikko Salomaa; P Eline Slagboom; Melanie Waldenberger; Samuli Ripatti; Mika Ala-Korpela Journal: Nat Commun Date: 2016-03-23 Impact factor: 14.919
Authors: Jordi Merino; Aaron Leong; Ching-Ti Liu; Bianca Porneala; Geoffrey A Walford; Marcin von Grotthuss; Thomas J Wang; Jason Flannick; Josée Dupuis; Daniel Levy; Robert E Gerszten; Jose C Florez; James B Meigs Journal: Diabetologia Date: 2018-04-06 Impact factor: 10.122
Authors: Rachel Kadakia; Denise M Scholtens; Gerald W Rouleau; Octavious Talbot; Olga R Ilkayeva; Tabitha George; Jami L Josefson Journal: J Pediatr Date: 2018-09-10 Impact factor: 4.406
Authors: Nicolai J Wewer Albrechtsen; Kristine Færch; Troels M Jensen; Daniel R Witte; Jens Pedersen; Yuvaraj Mahendran; Anna E Jonsson; Katrine D Galsgaard; Marie Winther-Sørensen; Signe S Torekov; Torsten Lauritzen; Oluf Pedersen; Filip K Knop; Torben Hansen; Marit E Jørgensen; Dorte Vistisen; Jens J Holst Journal: Diabetologia Date: 2018-01-05 Impact factor: 10.122